batirtze-areitio Batirtze Areitio Batirtze has over 5 years of experience in the biopharma and biotech industries. She joined ApexOnco in 2025 after working as an analyst at OncologyPipeline. She is a graduate of the University of Navarra, where she earned a degree in biochemistry. ESMO 2023 – duelling PD-1 drugs 18 October 2023 ESMO 2023 – Jiangsu Hengrui sets a low bar in KRAS G12D inhibition 18 October 2023 US Keytruda approval scoops one ESMO late-breaker 17 October 2023 ESMO 2023 – Merus gets a pre-meeting boost 17 October 2023 Keytruda’s 25th EU green light 16 October 2023 Triple meeting 2023 – no monotherapy activity for Repare 16 October 2023 Two BCL-2 inhibitors feature in phase 3 starts 13 October 2023 Merck kicks off its first TROP2 phase 3 11 October 2023 Load More